Artivion announced at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting that its AMDS PERSEVERE and PROTECT clinical trials showed high rates of organ perfusion improvement and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback